After exploring the science behind chemotherapy improving T cell trafficking into the tumour yesterday – which is one of the key rate limiting issues that need to be addressed with immunotherapies such as checkpoint blockade – some obvious follow-up questions comes to mind:
- Does the compelling data in mice translate to humans?
- Can chemotherapy turn a cold tumour into a hot one?
- Will patients have improved outcomes as a result – or not?
It’s easy to dismiss traditional therapies in favour of appealing new developments, but what happens when we combine them? Do we get additive effects, synergies or a negative impact?
As part of our ongoing AACR coverage, we explored this conundrum in the context of new data readouts, as well as the broader competitive landscape.
What we found was really interesting!
BMS, Merck and Genentech/Roche all have trials ongoing in the metastatic colorectal cancer space, with very different approaches being taken. Does it matter? Which one’s driving the bus? We summarise these trials and offer some strategic insights on this niche.
To learn more, subscribers can log-in or you can sign-up in the blue box below…